MedPath

Anti-Obesity Effect of Pediococcus Pentosaceus LP28

Not Applicable
Completed
Conditions
Obesity
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Live Pediococcus pentosaceus LP28
Dietary Supplement: Heat-killed Pediococcus pentosaceus LP28
Registration Number
NCT01685944
Lead Sponsor
Hiroshima University
Brief Summary

This study is designed to evaluate efficacy of Pediococcus pentosaceus LP28 in reducing body fat and body weight in subjects with BMI 25-30 kg/m2.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • BMI 25-30 kg/m2
Exclusion Criteria
  • Taking medicines or functional food that may affect body weight or body fat
  • Pregnant or nursing a child
  • Participation in any clinical trial within 90 days of the commencement of the trial
  • Renal or hepatic dysfunction
  • Heart disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Live Pediococcus pentosaceus LP28Live Pediococcus pentosaceus LP28-
Heat-killed Pediococcus pentosaceus LP28Heat-killed Pediococcus pentosaceus LP28-
Primary Outcome Measures
NameTimeMethod
BMIEvery day (Overall 14 weeks)

Body weight will be measured every morning.

Body fatEvery 4 weeks (Overall 12 weeks)
Secondary Outcome Measures
NameTimeMethod
Fasting insulinWeeks 0 and 12
AdiponectinWeeks 0 and 12
Abdominal circumferenceEvery 4 weeks (Overall 12 weeks)
Serum triglycerideEvery 4 weeks (Overall 12 weeks)
Total cholesterolEvery 4 weeks (Overall 12 weeks)
Fasting blood glucoseEvery 4 weeks (Overall 12 weeks)
HDL cholesterolEvery 4 weeks (Overall 12 weeks)
HOMA-RWeeks 0 and 12
LDL cholesterolEvery 4 weeks (Overall 12 weeks)
ResistinWeeks 0 and 12
LeptinWeeks 0 and 12

Trial Locations

Locations (1)

Hiroshima University

🇯🇵

Hiroshima, Japan

© Copyright 2025. All Rights Reserved by MedPath